News

Otsuka Pharmaceutical announced that it and Lundbeck will launch a third Phase 3 clinical trial of brexpiprazole to possibly treat agitation in patients with dementia linked to probable Alzheimer’s disease. Brexpiprazole, under the brand name Rexulti, was approved in the United States to treat people with schizophrenia and as an adjunct treatment…

Researchers have found that long-term use of opioids is not associated with an increased risk of Alzheimer’s disease (AD). The research was part of Finland’s nationwide MEDALZ study, and the findings were published in the journal Pain Medicine under the title “Is Alzheimer’s Disease Associated with Previous…

Researchers may have discovered the reason certain investigational therapies failed in Alzheimer’s disease clinical trials — a finding that could lead to new trials with a greater chance of success, according to a study published in the journal Cell Reports. A class of drugs, intended to block an enzyme…

A first-of-its-kind event, “A Women’s Health Summit: It Starts With the Brain,” set for today in New York, will focus on women’s brain health and Alzheimer’s disease. The summit is being co-organized by award-winning journalist Maria Shriver, founder of the Women’s Alzheimer’s Movement, and Nancy Dubuc, president and CEO…

Probiodrug‘s PQ912 decreased markers of inflammation and damage in the nerve cell connections of Alzheimer’s patients, according to a Phase 2a clinical trial. The company will present the results of the SAPHIR trial, which covered the therapy’s safety and effectiveness, at the 10th Clinical Trials on Alzheimer’s Disease Conference in…

AbbVie and Alector are partnering on developing and commercializing treatments for Alzheimer’s and other neurodegenerative diseases. Alector brings an immuno-neurology discovery platform to the partnership. AbbVie brings its expertise in research, development, and commercialization of therapies targeting Alzheimer’s. It has become increasingly clear that the immune system plays a key…

The Alzheimer’s Association and Alzheimer’s Drug Discovery Foundation will fund a Phase 2 clinical trial of a combination therapy that Amylyx Pharmaceuticals is developing for Alzheimer’s disease. Amylyx will receive $1.85 million for the trial of AMX0035, which consists of an oral formulation of sodium phenylbutyrate (PB) and tauroursodeoxycholic-acid…

Biogen  and Eisai have deepened their partnership by agreeing to work together on the continued development of the Alzheimer’s therapy aducanumab (BIIB037), which targets harmful beta amyloid protein clusters. The U.S. and Japanese companies are already collaborating on the development of elenbecestat (E2609) and BAN2401, which also target beta…

The U.S. Food and Drug Administration has granted Fast Track status to Alzheon’s Alzheimer’s therapy candidate ALZ-801, which studies have shown prevents the clustering of harmful proteins associated with the disease. “We look forward to working closely with the FDA as we seek to make progress in developing a…

The founders of Edelman Financial Services have donated $25 million to a group called the Alzheimer’s Disease Team to help it compete for a global XPRIZE. Jean and Ric Edelman announced the donation at the 2017 XPRIZE Visioneers Summit in Los Angeles on Oct. 19. The Alzheimer’s team, which received the…